1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,820 | 0,880 | 12.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 01.09. | RECBIO-B (02179): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 29.08. | RECBIO-B (02179): UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | - | HKEx | ||
| 19.08. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
| 11.08. | RECBIO-B (02179): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 11.08. | RECBIO-B (02179): ANNOUNCEMENT ON COMPLETION OF INDUSTRIAL AND COMMERCIAL REGISTRATION AND RENEWAL OF BUSINESS LICENSE IN RESPECT OF CHANGES IN BUSINESS ... | - | HKEx | ||
| 23.07. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO THE REPLY FROM THE CSRC ON ISSUANCE OF DOMESTIC SHARES | 1 | HKEx | ||
| 30.06. | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT PRODUCT LICENSING COOPERATION REGARDING THE RECOMBINANT HPV 9-VALENT VACCINE REC603 ESTABLISHED BETWEEN THE COMPANY ... | 2 | HKEx | ||
| 20.06. | RECBIO-B (02179): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025, APPOINTMENT OF THE BOARD OBSERVER AND AMENDMENTS TO THE ARTICLES OF ... | - | HKEx | ||
| 30.05. | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2024 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 20, 2025 | 2 | HKEx | ||
| 30.05. | RECBIO-B (02179): NOTICE OF 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 30.05. | RECBIO-B (02179): CIRCULAR OF 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| 21.05. | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 21.05. | RECBIO-B (02179): PROPOSED PARTICIPATION IN THE H SHARE FULL CIRCULATION PLAN BY THE COMPANY, PROPOSED CHANGES IN BUSINESS SCOPE, PROPOSED AMENDMENTS ... | - | HKEx | ||
| 22.04. | RECBIO-B (02179): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 22.04. | RECBIO-B (02179): 2024 ANNUAL REPORT | - | HKEx | ||
| 28.03. | RECBIO-B (02179): UPDATE ON THE QUALIFICATION OF THE JOINT COMPANY SECRETARY | 1 | HKEx | ||
| 28.03. | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND PROPOSED APPOINTMENT OF THE BOARD OBSERVER | - | HKEx | ||
| 18.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | +1,83 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| BIONTECH | 82,50 | +0,06 % | Evotec Aktie: Und nun?- Aixtron, BioNTech, Hensoldt, Knaus Tabbert und Smartbroker im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| ARCELLX | 76,19 | -1,92 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,110 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 38,885 | -0,29 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,710 | +8,94 % | Avidity Biosciences: BofA Securities erhöht Kursziel auf 65 US-Dollar | ||
| EVOTEC | 5,818 | -0,34 % | Evotec wird degradiert! Raus aus Hensoldt? Rein in die Pure Hydrogen Aktie? | Raus aus Hensoldt und rein in Rheinmetall? Dies sagen Analysten jedenfalls indirekt. Denn die Bewertung sorgt für Kopfschmerzen. Wie sehen andere Experten die Entwicklung der Aktie? Dagegen scheint... ► Artikel lesen | |
| TOURMALINE BIO | 47,600 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,750 | +2,37 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| MAZE THERAPEUTICS | 23,270 | -6,17 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,530 | -4,39 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,060 | -0,32 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| ENLIVEN THERAPEUTICS | 19,960 | +0,20 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 49,380 | -4,80 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,250 | -15,38 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen |
JIANGSU RECBIO TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,780 Euro und damit +2,63 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.